欧洲环境下季节性流感大规模疫苗接种策略的健康与经济影响:数学建模与成本效果分析
研究用年龄结构动态传播模型模拟8个欧洲地区2010/11至2017/18流感季,评估27种针对老年人和/或儿童的接种方案。
要点
- 老年人改用改良三价疫苗,每10万人感染数中位数减少261.5(范围154.4至475.7)。
- 儿童大规模接种四价疫苗通过间接保护使老年人每10万人感染数中位数减少266.5(范围65.7至477.9)。
核心结论
- 基于直接和间接保护,且取决于疫苗价格,模型结果支持在欧洲各场景中联合采取老年人改用改良疫苗和儿童普遍接种方案。
研究设计与样本
- 采用年龄结构动态传播模型,推断年龄和(亚)型特异性季节性流感病毒感染,校准至英格兰、法国、爱尔兰、纳瓦拉、荷兰、葡萄牙、苏格兰和西班牙2010/11至2017/18流感季数据。
- 研究覆盖8个欧洲场景(n=205.8百万),探索27种针对老年人和/或儿童的接种方案。
- 基础接种场景为非佐剂、非高剂量三价疫苗且无儿童普遍接种;从医疗保健视角估算场景特异性成本和获得的QALYs,QALYs按3.0%贴现。
主要发现
- 老年人改用改良三价疫苗后,每10万人感染数中位数减少261.5(场景范围154.4至475.7);改用非佐剂非高剂量四价疫苗后中位数减少150.8(范围77.6至262.3)。
- 儿童大规模接种三价疫苗(接种率25%)通过间接保护使老年人每10万人感染数中位数减少233.6(范围58.9至425.6);接种四价疫苗中位数减少266.5(范围65.7至477.9),并因避免感染在各年龄组带来实质性健康获益。
关键数值与推荐
- 老年人改用改良三价疫苗:每10万人感染数中位数减少261.5(范围154.4至475.7)。
- 老年人改用四价疫苗:每10万人感染数中位数减少150.8(范围77.6至262.3)。
- 儿童大规模接种三价疫苗(接种率25%):老年人每10万人感染数中位数减少233.6(范围58.9至425.6)。
- 儿童大规模接种四价疫苗(接种率25%):老年人每10万人感染数中位数减少266.5(范围65.7至477.9)。
临床怎么用
- 原文结论支持老年人改用改良疫苗并联合儿童普遍接种方案,效果取决于疫苗价格。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite seasonal influenza vaccination programmes in most countries targeting individuals aged ≥ 65 (or ≥ 55) years and high risk-groups, significant disease burden remains. We explored the impact and cost-effectiveness of 27 vaccination programmes targeting the elderly and/or children in eight European settings (n = 205.8 million). METHODS: We used an age-structured dynamic-transmission model to infer age- and (sub-)type-specific seasonal influenza virus infections calibrated to England, France, Ireland, Navarra, The Netherlands, Portugal, Scotland, and Spain between 2010/11 and 2017/18. The base-case vaccination scenario consisted of non-adjuvanted, non-high dose trivalent vaccines (TV) and no universal paediatric vaccination. We explored i) moving the elderly to "improved" (i.e., adjuvanted or high-dose) trivalent vaccines (iTV) or non-adjuvanted non-high-dose quadrivalent vaccines (QV); ii) adopting mass paediatric vaccination with TV or QV; and iii) combining the elderly and paediatric strategies. We estimated setting-specific costs and quality-adjusted life years (QALYs) gained from the healthcare perspective, and discounted QALYs at 3.0%. RESULTS: In the elderly, the estimated numbers of infection per 100,000 population are reduced by a median of 261.5 (range across settings: 154.4, 475.7) when moving the elderly to iTV and by 150.8 (77.6, 262.3) when moving them to QV. Through indirect protection, adopting mass paediatric programmes with 25% uptake achieves similar reductions in the elderly of 233.6 using TV (range: 58.9, 425.6) or 266.5 using QV (65.7, 477.9), with substantial health gains from averted infections across ages. At €35,000/QALY gained, moving the elderly to iTV plus adopting mass paediatric QV programmes provides the highest mean net benefits and probabilities of being cost-effective in all settings and paediatric coverage levels. CONCLUSION: Given the direct and indirect protection, and depending on the vaccine prices, model results support a combination of having moved the elderly to an improved vaccine and adopting universal paediatric vaccination programmes across the European settings.
引用
- Sandmann FG, van Leeuwen E, Bernard-Stoecklin S, et al. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis. Vaccine. 2022. PMID: 35109968. doi:10.1016/j.vaccine.2022.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。